Coherus BioSciences Inc Total Assets
Coherus BioSciences Inc total assets. Based on the latest financial reports, Coherus BioSciences Inc (CHRS) holds total assets worth $191.18 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Coherus BioSciences Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Coherus BioSciences Inc (2012–2025)
Total assets of Coherus BioSciences Inc from 2012 to 2025. This chart illustrates how Coherus BioSciences Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Coherus BioSciences Inc for real-time trading data and today's change.
Coherus BioSciences Inc - Asset Composition Analysis
Coherus BioSciences Inc Total Assets Breakdown (December 2025)
Coherus BioSciences Inc total assets breakdown as of December 2025. Coherus BioSciences Inc's total assets of $191.18 Million consist of 80.0% current assets and 20.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.4% |
| Accounts Receivable | $18.42 Million | 7.1% |
| Inventory | $3.17 Million | 1.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $46.24 Million | 17.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Coherus BioSciences Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Coherus BioSciences Inc's current assets represent 80.0% of total assets in 2025, a decrease from 93.5% in 2012.
- Cash Position: Cash and equivalents constituted 34.4% of total assets in 2025, down from 54.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 17.9% of total assets.
Coherus BioSciences Inc Competitors by Total Assets
Key competitors of Coherus BioSciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Coherus BioSciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.77 | 1.43 | 2.10 |
| Quick Ratio | 1.70 | 1.42 | 1.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $58.28 Million | $115.09 Million | $352.69 Million |
Coherus BioSciences Inc - Advanced Valuation Insights
This section examines the relationship between Coherus BioSciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.35 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | -42.4% |
| Total Assets | $258.34 Million |
| Market Capitalization | $124.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Coherus BioSciences Inc's assets below their book value (0.48x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Coherus BioSciences Inc's assets decreased by 42.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Coherus BioSciences Inc (2012–2025)
The table below shows the annual total assets of Coherus BioSciences Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $258.34 Million | -42.40% |
| 2024-12-31 | $448.53 Million | -28.76% |
| 2023-12-31 | $629.60 Million | +30.94% |
| 2022-12-31 | $480.85 Million | -29.22% |
| 2021-12-31 | $679.33 Million | -19.29% |
| 2020-12-31 | $841.65 Million | +105.82% |
| 2019-12-31 | $408.93 Million | +311.12% |
| 2018-12-31 | $99.47 Million | -38.83% |
| 2017-12-31 | $162.61 Million | -8.89% |
| 2016-12-31 | $178.49 Million | -15.96% |
| 2015-12-31 | $212.38 Million | +13.44% |
| 2014-12-31 | $187.22 Million | +294.59% |
| 2013-12-31 | $47.45 Million | +78.82% |
| 2012-12-31 | $26.53 Million | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more